Hi Hoyland, your quote below is the creative loop hole I am surprised Nant has not capitalized on by running more of their cancer programs through Benitec.
"Also, the "grant" is a R&D tax incentive and so the more we spend on R&D, the more we can claim back." (non dilutive funding)
Why wouldn't Nant do a lot of R&D for cancer through Benitec where you would receive a tax credit & beneficial dollar exchange rate?
At the end of the day Nant's core focus is on cancer not AMD, OPMD or HBV.
I Agree we should partner OPMD with big pharma to get get more upfront non -dilutive capital and get some much needed creditability.
Jerel Banks is the chairman has a vested interest in making sure Benitec focuses on Car-t joint ventures to please his boss Patrick Soon.
Our partner Regen BioPharma, dCellVax Gene-Silenced Breast cancer immunotherapy is where we could allocate some of our opmd money to help develop dCellVax for a larger equity stake in the program.
BLT Price at posting:
22.0¢ Sentiment: Buy Disclosure: Held
